Purpose and Editorial Scope
Our articles address U.S. human ivermectin medicines, including prescription oral tablets, ivermectin cream 1% for inflammatory rosacea lesions and OTC ivermectin lotion 0.5% for head lice. Related guides address FDA-labeled indications, off-label clinical contexts, product comparisons, pharmacology, medication safety and lawful pharmacy access. Pages should serve a defined reader question rather than combine unrelated intents.
Information is educational and must not be framed as an individualized medical recommendation, guaranteed treatment, prescription approval or offer from IverMedX to dispense medication. Our About page summarizes the site’s mission, and Terms of Use covers important limitations.
Source Hierarchy and Primary Documents
For U.S. drug approval, registered indications and product identity, we favor current FDA approvals, the Orange Book, the relevant prescribing information and FDA Drug Facts labeling. DailyMed is useful for exact submitted labels, ingredient strengths, contraindications, administration routes, manufacturer or labeler details and NDC-linked package information. CDC guidance is used for relevant parasitic diseases, including scabies.
Peer-reviewed studies, systematic reviews and professional guidelines support descriptions of clinical evidence, but source type and study quality should be identified. Secondary consumer resources may clarify terminology; they should not replace an FDA label or original study when a claim requires precise regulatory or numerical support.
Approval, Labeling, Marketing and Inventory Are Different Facts
An FDA-approved drug may no longer be marketed by an original brand manufacturer. A product may appear in the Orange Book or a label archive even when a particular package is not actively distributed. NDC listing does not by itself prove FDA approval, current inventory or seller authenticity. We aim to identify which question a source answers before describing a product as available.
The distinction is particularly important for Stromectol and historical branded tablet strengths, as well as Sklice and Soolantra brand and generic product listings. Where a claim depends on current marketing status, it should be verified with an up-to-date authoritative record or framed as unconfirmed, not inferred from old packaging or a cached store result.
Precise Separation of Formulations and Indications
Oral ivermectin tablets, ivermectin cream 1% and ivermectin lotion 0.5% have separate labeled uses and access categories. Oral tablets are prescription medications approved for specified parasitic infections; rosacea cream is prescription; the head-lice lotion has OTC labeling following an FDA Rx-to-OTC switch. An approved indication for one formulation cannot be extended automatically to another.
We distinguish off-label prescribing from FDA approval. Oral ivermectin for scabies is discussed in CDC clinical guidance but is not FDA-approved for that indication. Ivermectin is not FDA-approved or authorized to prevent or treat COVID-19. We do not recommend veterinary ivermectin for people or present preliminary or mechanistic findings as established clinical benefit.
Clinical Evidence and Comparison Claims
When comparing medicines, we specify the exact products, strengths, vehicles, participant populations, follow-up windows and measured outcomes. A trial comparing ivermectin cream with metronidazole 0.75% cream should not be used to rank all metronidazole formulations. A combination-therapy study cannot be described as a direct monotherapy-versus-monotherapy comparison.
Numerical results require context: effect size, outcome definition, time point and key limitations. Observational studies, network meta-analyses and mechanistic studies do not provide identical certainty. We avoid blanket claims of superiority, guaranteed cure or safety for all patients when the evidence addresses a narrower question.
Medical Accuracy and Review Standards
Content involving contraindications, drug interactions, children, pregnancy or breastfeeding, adverse reactions, dosing boundaries and disputed indications is prioritized for close source checking. A qualified health professional may be needed to assess clinical interpretation beyond direct label facts. The Medical Review Policy details this framework.
A page must not be marked “medically reviewed” merely because the site has a policy or because automated drafting tools were used. Where an actual named review occurs, the reviewer’s credentials and article-specific attribution should be documented. Our Medical Reviewer page sets out that transparency principle.
Product, Brand and Generic Comparisons
We separate a trade name from its generic ingredient and distinguish the reference product from individual FDA-approved generic applications. Therapeutic equivalence should be described using the actual FDA determination and the corresponding strength and formulation; it should not be inferred from an ingredient name alone or borrowed from an unrelated strength.
Packaging, color, imprint, NDC, labeler and inactive ingredients may differ between approved products. These differences should not automatically be presented as evidence that a brand is better or worse. Pharmacy substitution must follow the prescription, applicable law and pharmacist judgment.
Commercial Independence and Affiliate Links
IverMedX may include advertising or affiliate links to independently operated websites. When a link has a commercial relationship, it should be presented so readers can recognize its nature; sponsored links should use appropriate link attributes. Referral compensation must not be represented as medical evidence or a guarantee of a safe seller.
We do not claim that a third-party site is FDA-endorsed or that a pharmacy is properly licensed without verification. No commercial offer should be used to justify bypassing a prescription, choosing a different strength or substituting animal products. Questions about specific sponsored placements can be sent through Contact.
Prices, Availability and Insurance as Changing Information
Prices, discounts, insurance formularies, prior-authorization rules, pharmacy networks and individual stock are time-sensitive. Our cost articles generally explain durable factors rather than publish fixed dollar amounts or guarantees of savings. A quote from one pharmacy or an old online comparison is not a universal U.S. price.
We ask readers to verify the exact product, amount, payment method and benefit status with the pharmacy or insurer. An article may explain how to check coverage without asserting that a particular plan will pay. Current conditions should be labeled as current only when independently supported.
Corrections, Updates and Reader Reports
Material factual concerns should be assessed against reliable records, not solved by adding unsupported wording. Examples include a changed FDA drug status, a withdrawn or revised label, an incorrect age boundary, an inaccurate clinical outcome or an unsafe statement about drug substitution. We aim to correct substantiated errors and revisit affected pages when important evidence or regulations change.
Readers can submit a correction using Contact, ideally including the page URL, the specific statement and a supporting source. We do not promise a fixed revision frequency or claim that every page has been independently re-reviewed on a particular date unless this has actually occurred.